B
Bull
Bull · 25%NOTV
$2.18
Szenariopreis
$0.080
-0.013 (-15.89%)Zum Schluss
Loading chart…
- High
- 0.098
- Open
- 0.085
- VWAP
- 0.09
- Vol
- 17.27M
- Mkt Cap
- 44.93M
- Low
- 0.080
- Amount
- 1.48M
- EV/EBITDA, TTM
- -14.11
Inotiv, Inc. is a contract research company engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through DSA segment, it supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through RMS segment, it offers access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.
Bewertungskennzahlen
The current forward P/E ratio for Inotiv Inc (NOTV) is 3.72, compared to its 5-year average forward P/E of -0.43.
Alphio AI Price Scenarios for NOTV
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Event-Zeitleiste
News
9.007-20NewsfilterInotiv Emerges from Chapter 11 with Stronger Balance Sheet
- 9.007-14Newsfilter
Inotiv Confirms Reorganization Plan, Strengthening Financial Structure
9.006-03seekingalphaInotiv Files for Chapter 11 Bankruptcy Protection
- 9.006-03Newsfilter
Inotiv Secures $65 Million Financing for Restructuring
9.003-18seekingalphaFDA Issues Draft Guidance on Alternatives to Animal Testing
NOTV FAQ — answered by Alphio AI
Inotiv, Inc. is a contract research company engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through DSA segment, it supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through RMS segment, it offers access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas. It operates in the Healthcare sector (SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry).
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.